London, England, January 2th, 2025 - ZayaAI, a trailblazer in artificial intelligence (AI) solutions for healthcare, proudly announces the appointment of Kimberly Gasuad to its Board of Directors. With decades of experience in healthcare innovation and strategic leadership, Gasuad’s addition marks a pivotal milestone in ZayaAI’s mission to revolutionize pathology diagnostics and enhance global healthcare outcomes.
“We are honored to welcome Kimberly Gasuad to our Board,” stated Cristian Mogodici, CEO of ZayaAI. “Her extensive expertise in healthcare and AI-driven innovation will play a crucial role in steering ZayaAI’s strategic initiatives. Kimberly’s leadership aligns with our vision to empower pathologists and healthcare professionals with groundbreaking technology, making disease diagnosis faster, more accurate, and more accessible worldwide.”
Transforming Pathology with AI
ZayaAI, founded in 2020 in Bucharest, Romania, specializes in digital pathology—a rapidly growing field that integrates the science of pathology with cutting-edge AI and deep learning technologies. The company’s flagship products, ZayaAI Dx and ZayaAI Telepathology Dx, are designed to revolutionize disease diagnostics. By leveraging advanced AI algorithms, these solutions assist medical professionals, including hospital pathologists and pharmaceutical researchers, in analyzing tissue and cell images with unparalleled speed and precision.
The company's AI models are particularly impactful in diagnosing oncological diseases, dermato-pathology cases, and infectious diseases, where timely and accurate results are critical. ZayaAI’s technology reduces the time required for diagnosis while enhancing the reliability of results, enabling healthcare providers to deliver better patient outcomes.
Strengthening leadership for strategic growth
Kimberly Gasuad’s appointment follows a series of strategic moves by ZayaAI to expand its leadership team and position itself as a global leader in AI-driven healthcare. Earlier this year, ZayaAI announced collaborations with Christophe Bourrilly, a healthcare financing expert, and Alina Clont, a business development consultant specializing in life sciences. These partnerships reflect ZayaAI’s commitment to innovation, scalability, and industry impact.
“Joining ZayaAI’s Board is an exciting opportunity to contribute to the advancement of AI in pathology,” said Kimberly Gasuad. “ZayaAI’s dedication to transforming disease diagnosis resonates deeply with my passion for improving healthcare systems through technology. I look forward to working closely with the team to unlock new possibilities in digital pathology.”
Recent milestones and collaborations
ZayaAI has achieved several notable milestones in 2024, including expanded partnerships with healthcare providers and pharmaceutical companies. These collaborations have allowed the company to refine its AI models and scale its solutions to meet the demands of a rapidly evolving healthcare landscape.
One highlight includes the integration of ZayaAI Dx into leading hospitals across Europe, where it has demonstrated significant improvements in diagnostic efficiency. Additionally, the company’s telepathology platform has gained traction among pharmaceutical companies for its ability to streamline research workflows and support remote diagnostics.
“ZayaAI’s growth is a testament to our team’s relentless pursuit of excellence,” added Mogodici. “Our focus remains on delivering state-of-the-art solutions that address the challenges faced by pathologists and healthcare providers globally. Kimberly’s insights and experience will undoubtedly amplify our efforts to innovate and scale our technology.”
Who stands behind ZayaAI?
This partnership brings confidence to the ZayaAI community and key stakeholders, including investors such as Oddyiana Ventures and Iron Capital, underscoring robust demand for their services and the $ZAYA token. It reflects ZayaAI's commitment to long-term value for token holders and a thriving community.
About ZayaAI
ZayaAI is a digital pathology company dedicated to improving disease diagnosis through the integration of artificial intelligence and machine learning. By combining the expertise of pathologists with the power of AI, ZayaAI aims to make diagnostic processes faster, more accurate, and more efficient.
Founded in 2020 in Bucharest, Romania, ZayaAI has rapidly emerged as a leader in the field, serving hospitals, pharmaceutical companies, and research institutions. Its solutions are tailored to meet the unique challenges of modern pathology, empowering healthcare professionals to make data-driven decisions that save lives.
For more information about ZayaAI and its innovative solutions, visit www.zaya.ai.
Where to buy ZAYA?
Stay tuned, ZAYA TGE is coming soon, follow our socials and CoinMarketCap.
ZayaAI team said:
“We are thrilled that Rollman Management Digital is making this investment and it will help together with our other investors and partners to bring ZayaAI to the next level.”
For more information, visit:
X, Facebook, YouTube, and LinkedIn.
Contact: contact: @zaya.ai
About Rollman Management Digital
Rollman Management Digital is a private investment and management consulting boutique that is incorporated in the British Virgin Islands. The firm seeks to invest in talented teams and their blockchain protocols to further develop their technology and business while adding significant value to the future of the modern economy.
RMD is led by Victor R. Ch. Rollman, the founder of Rollman Capital, Rollman Mining, and Rollman Management. The Group offers a wide range of investment opportunities, financial services, and management consultancy to UHNWIs, entrepreneurs, developing governments, commodity trading firms, banks, family offices, and pension funds.
Website: https://rollmanmanagement.com/